| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC3121 |
| Trial ID | NCT05465902 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | Pfizer COVID-19 Vaccine|Moderna COVID-19 Vaccine |
| Co-treatment | Recombinant COVID-19 variant Vaccine (Sf9 Cell)|COVID-19 Vaccine (Vero Cell)|Viral Vector COVID-19 vaccine (AstraZeneca) |
| Location approved | US, Canada, Israel, EU, Switzerland, Singapore, Qatar, Vietnam, UK, Philippines, Thailand, Japan, South Korea, Brunei, Paraguay, China, Botswana, India, Indonesia, Saudi Arabia, Mexico, Australia, Nigeria, Colombia |
| Phase | Phase2 |
| Recruitment status | Not Recruiting |
| Title | Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster Following Primary Vaccination of Either Inactivated or mRNA or Viral Vector COVID-19 Vaccines |
| Year | 2023 |
| Country | Mexico |
| Company sponsor | WestVac Biopharma Co., Ltd. |
| Other ID(s) | JSVCT149 |
| Vector information | |||
|
|||
| Cohort1: Recombinant COVID-19 variant Vaccine (Sf9 Cell) | |||||||||
|
|||||||||
| Cohort2: COVID-19 Vaccine (Vero Cell) | |||||||||
|
|||||||||
| Cohort3: mRNA COVID-19 vaccine (Moderna) | |||||||||
|
|||||||||
| Cohort4: Viral Vector COVID-19 vaccine (AstraZeneca) | |||||||||
|
|||||||||